News

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 17, 2017, to discuss ImmunoGen's financial results for the six-month period and quarter ended December 31, 2016. Management also will provide a brief update on the business.

To access the live call by phone, dial 719-457-2627; the conference ID is 4132697. The call also may be accessed through the Investors section of the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through March 3, 2017.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla^®, in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.

Kadcyla^® is a registered trademark of Genentech, a member of the Roche Group.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170125006153/en/

For Investors
ImmunoGen, Inc.
Sarah Kiely, 781-895-0600
sarah.kiely@immunogen.com
or
For Media
ImmunoGen, Inc.
Amy Reilly, 781-895-0138
amy.reilly@immunogen.com
or
FTI Consulting Inc.
Robert Stanislaro, 212-850-5657
Robert.Stanislaro@fticonsulting.com

Source: ImmunoGen, Inc.

News Provided by Acquire Media